Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 141.3%

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 636,132 shares, a growth of 141.3% from the June 15th total of 263,601 shares. Currently, 0.8% of the company’s stock are short sold. Based on an average daily trading volume, of 459,329 shares, the short-interest ratio is currently 1.4 days.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SOPH shares. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Hold” and a consensus target price of $7.50.

Insider Activity

In other SOPHiA GENETICS news, CTO Abhimanyu Verma sold 5,285 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.10, for a total value of $26,953.50. Following the completion of the transaction, the chief technology officer owned 192,171 shares in the company, valued at $980,072.10. This represents a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 7,393 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.17, for a total value of $38,221.81. Following the completion of the sale, the insider directly owned 614,887 shares of the company’s stock, valued at $3,178,965.79. The trade was a 1.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 184,270 shares of company stock worth $999,267 over the last three months. Company insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of large investors have recently made changes to their positions in the stock. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the fourth quarter worth about $49,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at approximately $49,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS during the 1st quarter valued at approximately $50,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter worth approximately $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Price Performance

Shares of SOPH traded down $0.01 during mid-day trading on Thursday, hitting $5.76. The company’s stock had a trading volume of 51,795 shares, compared to its average volume of 189,775. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The firm has a 50-day simple moving average of $5.21 and a 200 day simple moving average of $5.01. The firm has a market capitalization of $483.15 million, a P/E ratio of -11.04 and a beta of 0.96. SOPHiA GENETICS has a 1-year low of $2.92 and a 1-year high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.